Related references
Note: Only part of the references are listed.Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
Mona-Elisabeth Revheim et al.
ACTA ONCOLOGICA (2013)
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial
A. Patrikidou et al.
ANNALS OF ONCOLOGY (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
Maria T. Petrucci et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
Man Yu et al.
CANCER AND METASTASIS REVIEWS (2013)
A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs
Eric Guerin et al.
CANCER RESEARCH (2013)
A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer
Fausto Petrelli et al.
CLINICAL BREAST CANCER (2013)
Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival
M. Faehling et al.
LUNG CANCER (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Transient Sunitinib Resistance in Gastrointestinal Stromal Tumors
Raffaella Bracci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
Antonija Kreso et al.
SCIENCE (2013)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
Antoine Italiano et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Sorafenib rechallenge in patients with metastatic renal cell carcinoma
Masahiro Nozawa et al.
BJU INTERNATIONAL (2012)
Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer
Matthias M. Heck et al.
BJU INTERNATIONAL (2012)
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2012)
Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions
M. Pegram et al.
CLINICAL BREAST CANCER (2012)
Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
Lorenzo Fornaro et al.
CLINICAL COLORECTAL CANCER (2012)
Bevacizumab rechallenge after first line maintenance bevacizumab
Panagiotis A. Konstantinopoulos et al.
GYNECOLOGIC ONCOLOGY (2012)
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
Lawrence N. Shulman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
Kenichi Nishie et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study
In-Jae Oh et al.
LUNG CANCER (2012)
Treatment selection in metastatic renal cell carcinoma: expert consensus
Bernard Escudier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
S. Sivanand et al.
Science Translational Medicine (2012)
LGR5-Positive Colon Cancer Stem Cells Interconvert with Drug-Resistant LGR5-Negative Cells and Are Capable of Tumor Reconstitution
Shinta Kobayashi et al.
STEM CELLS (2012)
Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment
Su Jin Yoo et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2012)
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
Michael Fiegl et al.
ANNALS OF HEMATOLOGY (2011)
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
Giuseppe Di Lorenzo et al.
BJU INTERNATIONAL (2011)
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
Renhua Guo et al.
BMC CANCER (2011)
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
Manuela Campiglio et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts
Mothaffar F. Rimawi et al.
CLINICAL CANCER RESEARCH (2011)
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A. Becker et al.
EUROPEAN JOURNAL OF CANCER (2011)
Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population
P. Reichardt et al.
EUROPEAN JOURNAL OF CANCER (2011)
Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Alessandra Gennari et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
Xiaoen Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
Kaijie He et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Richard A. Adams et al.
LANCET ONCOLOGY (2011)
Rechallenge with temozolomide in recurrent glioma
P. Gaviani et al.
NEUROLOGICAL SCIENCES (2011)
Bending the Cost Curve in Cancer Care
Thomas J. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC
Viktor Gruenwald et al.
ONKOLOGIE (2011)
Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
Liang Zhang et al.
PLOS ONE (2011)
Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
Ellen Weisberg et al.
PLOS ONE (2011)
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
Jean-Christophe Eymard et al.
BJU INTERNATIONAL (2010)
Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma Patients
Ivan N. Zama et al.
CANCER (2010)
Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized
Elsa Quintana et al.
CANCER CELL (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Chemotherapy Resistance and Retreatment: A Dogma Revisited
Aung Naing et al.
CLINICAL COLORECTAL CANCER (2010)
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
Yohann Loriot et al.
EUROPEAN JOURNAL OF CANCER (2010)
The therapeutic promise of the cancer stem cell concept
Natasha Y. Frank et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
Hans J. Hammers et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Kae Hashimoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
Axel Le Cesne et al.
LANCET ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
Yoshio Tomizawa et al.
LUNG CANCER (2010)
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan et al.
NATURE (2010)
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
Carlo Palmieri et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
Jean-Marc Extra et al.
ONCOLOGIST (2010)
Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment
Marcus Alexander Woerns et al.
ONCOLOGY (2010)
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Hajime Asahina et al.
ONCOLOGY (2010)
Bortezomib Retreatment in Relapsed Multiple Myeloma - Results from a Retrospective Multicentre Survey in Germany and Switzerland
I. Hrusovsky et al.
ONCOLOGY (2010)
Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer
Axel Grothey
ONCOLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
Terence C. Tang et al.
NEOPLASIA (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Benoist Chibaudel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Rechallenge with temozolomide in patients with recurrent gliomas
Antje Wick et al.
JOURNAL OF NEUROLOGY (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
Cristina Morales et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2009)
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
D. H. Lee et al.
ANNALS OF ONCOLOGY (2008)
Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy
R. A. Cox et al.
BRITISH JOURNAL OF CANCER (2008)
A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
J. Shamash et al.
BRITISH JOURNAL OF CANCER (2008)
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer - Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
Tomasz M. Beer et al.
CANCER (2008)
Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule The Rescue Approach
James R. Perry et al.
CANCER (2008)
Stopping treatment can reverse acquired resistance to letrozole
Gattri J. Salnis et al.
CANCER RESEARCH (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Axel Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: A randomized trial
Serge Leyvraz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Lung cancer response to gefitinib, then erlotinib, then gefitinib again
Alvin S. Wong et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Dynamic Proteomics of Individual Cancer Cells in Response to a Drug
A. A. Cohen et al.
SCIENCE (2008)
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
Bostjan Seruga et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
Giuseppe Cancello et al.
BREAST CANCER RESEARCH (2008)
Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy
Nicoletta Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
Aimery de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group
A. Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years
A. de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Hiroshi Yokouchi et al.
BMC CANCER (2007)
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group
Jean-Yves Blay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer - Results from the SOCRATES retrospective study
Sandro Pignata et al.
ONCOLOGY (2006)
Salvage temozolomide for prior temozolomide responders
E Franceschi et al.
CANCER (2005)
Repopulation of cancer cells during therapy: An important cause of treatment failure
JJ Kim et al.
NATURE REVIEWS CANCER (2005)
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel
DB Solit et al.
CLINICAL CANCER RESEARCH (2005)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
D Tripathy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer
F Maindrault-Goebel et al.
ANNALS OF ONCOLOGY (2004)
Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells
J Deschatrette et al.
ANTI-CANCER DRUGS (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance
T Kurata et al.
ANNALS OF ONCOLOGY (2004)
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
V Nardi et al.
CURRENT OPINION IN HEMATOLOGY (2004)
Intermittent chemotherapy in metastatic androgen-independent prostate cancer
TM Beer et al.
BRITISH JOURNAL OF CANCER (2003)
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
ML Rothenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial
TS Maughan et al.
LANCET (2003)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914)
P Sonneveld et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance
S Cara et al.
ANNALS OF ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
